MedTrace Logo

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

NCT04724369 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-04-03

No results posted yet for this study

Summary

This is a Phase 3 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for confirming or excluding the presence of neuroblastoma

Conditions

Interventions

DRUG

18F-MFBG

Positron-emitting tomography (PET) (either PET/CT or PET/MR) imaging agent

Sponsors & Collaborators

  • New Approaches to Neuroblastoma Therapy Consortium

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    collaborator OTHER

  • Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-18
Primary Completion
2026-07-30
Completion
2026-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04724369 on ClinicalTrials.gov